Pill Identifier App

Tacrolimus Topical Dosage

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Atopic Dermatitis

Initial dose: Apply a thin layer to the affected areas twice daily and rub in gently and completely.
Maintenance dose: Continue for 1 week after resolution of symptoms.

Usual Pediatric Dose for Atopic Dermatitis

<2 years: Safety and efficacy have not been established.

2 to 15 years:
0.03% ointment: Apply a thin layer to the affected areas twice daily and rub in gently and completely. Continue for 1 week after resolution of symptoms.
0.1% ointment: Safety and efficacy have not been established.

>15 years:
0.03 or 0.1% ointment: Apply a thin layer to the affected areas twice daily and rub in gently and completely. Continue for 1 week after resolution of symptoms.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Avoid or minimize exposure to natural and artificial sunlight.

Before applying tacrolimus topical to the skin, patients should make sure that the skin is completely dry.

Occlusive dressings should be avoided.

There are rare reports of malignancy (such as skin and lymphoma) in patients treated with calcineurin inhibitors, including tacrolimus; however, a causal relationship has not been established. It is recommended to avoid long-term treatment with these agents, to limit application to areas of involvement with atopic dermatitis, and to avoid use in the treatment of unapproved indications.

Tacrolimus topical is not approved by the FDA for treatment of children less than 2- years- old.

Dialysis

There are no data on the hemodialysis and peritoneal dialysis clearance of tacrolimus topical. Due to its extensive plasma protein and erythrocyte binding, it is not expected to be dialyzable.

Other Comments

If clinical improvement is not observed within 2 weeks of starting treatment, topical therapy with tacrolimus should be discontinued.

Hide
(web1)